Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection



Status:Terminated
Conditions:Cancer, Cancer, Pancreatic Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:7/2/2016
Start Date:March 2010
End Date:June 2012

Use our guide to learn which trials are right for you!

Prognostic Value of Baseline CT Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection

The purpose of this study is first, to determine whether baseline perfusion characteristics
of pancreatic cancer, as characterized by CT perfusion studies, can predict tumor response
to treatment by stereotactic body radiotherapy (SBRT). The second goal of this study is to
determine whether baseline perfusion characteristics in those patients with resectable
pancreatic cancer correlate with immunohistologic markers of angiogenesis such as
microvessel density and vascular endothelial growth factor (VEGF) expression.


Inclusion Criteria:

1. suspected and/or biopsy-proven pancreatic adenocarcinoma, and

2. referral to Radiology for pre-treatment baseline pancreatic protocol CT.

Exclusion criteria:

1) are absolute contraindications to intravenous iodinated contrast or CT scan.
We found this trial at
1
site
291 Campus Dr
Stanford, California 94305
(650) 725-3900
Stanford University School of Medicine Vast in both its physical scale and its impact on...
?
mi
from
Stanford, CA
Click here to add this to my saved trials